---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-129357"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:49:01.510040+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Vor Bio appoints Blueprint R&D President Fouad Namouni to Board of Directors

## Summary
- Appointed independent Class II director effective April 30, 2024; term until 2026 annual meeting.
- Dr. Namouni has over 20 years oncology drug development; currently President of R&D at Blueprint Medicines.
- Receives standard non-employee director compensation: $40,000 cash retainer plus 60,000 stock option.
- Company highlights his experience in cell/genome engineering for acute myeloid leukemia pipeline.

## SEC filing metadata
- accession: 0001193125-24-129357
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312524129357/0001193125-24-129357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312524129357/d801460d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-129357
- JSON: https://secwatch.observer/filing/0001193125-24-129357.json
- Plain text: https://secwatch.observer/filing/0001193125-24-129357.txt

## Key facts
- Executive change
  Fouad Namouni was appointed as Director at Vor Biopharma Inc..
  - Action: appointed
  - Role: Director
  source text: On April 30, 2024, the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) increased the size of the Board from six to seven members and appointed Fouad Namouni, M.D., to fill the resulting vacancy, to serve on the Board as an independent Class II director, until the Company’s 2026 annual meeting of stockholders and until his successor is duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817229/000119312524129357/0001193125-24-129357-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.